Ronald Harold Wilfred Cooper - Oct 24, 2022 Form 4/A - Amendment Insider Report for ALBIREO PHARMA, INC. (ALBO)

Role
President and CEO, Director
Signature
/s/ Jason Duncan, Attorney-in-fact
Stock symbol
ALBO
Transactions as of
Oct 24, 2022
Transactions value $
-$17,991
Form type
4/A - Amendment
Date filed
1/9/2023, 05:40 PM
Date Of Original Report
Oct 25, 2022
Previous filing
Jul 25, 2022
Next filing
Jan 9, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALBO Common Stock Sale -$18K -919 -1.55% $19.58 58.5K Oct 24, 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
F2 Represents 31,106 shares of common stock and 27,395 restricted stock units. Includes 534 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan (the "ESPP") on May 31, 2019; 483 shares of common stock acquired under the ESPP on November 30, 2019; 1,205 shares of common stock acquired under the ESPP on May 31, 2020; and 818 shares of common stock acquired under the ESPP on May 31, 2021.

Remarks:

This amended Form 4 is being filed solely to report the acquisition of an aggregate of 3,040 additional shares of common stock under the ESPP on May 31, 2019, November 30, 2019, May 31, 2020 and May 31, 2021, as described in footnote 2 above.